Iovance Biotherapeutics (IOVA) Set to Announce Earnings on Thursday

Key Points

• Iovance Biotherapeutics is scheduled to report Q3 2026 results before the market opens on November 5. Analysts expect a loss of $0.085 per share and revenue of approximately $115.53 million, versus $99.31 million in revenue a year earlier.
• The company recently reported better-than-expected quarterly results, while positive lifileucel data in lung cancer and other solid tumors could expand opportunities beyond its approved Amtagvi melanoma treatment.
• Analyst sentiment is broadly favorable, with a consensus “Moderate Buy” rating and an average price target of $13.20, though some caution that the stock’s sharp rally may already reflect recent clinical-data gains and leave it vulnerable to profit-taking.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Iovance Biotherapeutics to announce earnings of ($0.0850) per share and revenue of $115.53 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The firm had revenue of $99.31 million during the quarter, compared to analyst estimates of $87.83 million. During the same period in the previous year, the business posted ($0.33) earnings per share. The business's revenue for the quarter was up 65.7% on a year-over-year basis. On average, analysts expect Iovance Biotherapeutics to post ($0.45) EPS for the current fiscal year and ($0.22) EPS for the next fiscal year.

Iovance Biotherapeutics Stock Up 1.6%

IOVA opened at $14.81 on Thursday. The firm has a 50 day moving average price of $11.35 and a 200-day moving average price of $5.76. Iovance Biotherapeutics has a twelve month low of $1.76 and a twelve month high of $15.37. The stock has a market capitalization of $6.71 billion, a price-to-earnings ratio of -20.29 and a beta of 0.76.

Wall Street Analyst Weigh In

A number of research firms have commented on IOVA. Wells Fargo & Company lifted their target price on shares of Iovance Biotherapeutics from $14.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 30th. TD Cowen raised their price target on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Monday, August 24th. Citizens Jmp raised their price target on Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a "market outperform" rating in a research note on Friday, August 7th. Mizuho lifted their price objective on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Iovance Biotherapeutics in a research report on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $13.20.

Key Headlines Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance will host a webcast on October 29 to present positive results from Phase 2 registrational cohorts of lifileucel in previously treated nonsquamous metastatic non-small cell lung cancer. Management will also discuss precision-medicine opportunities for its TIL platform, potentially providing a new growth avenue beyond the company’s approved Amtagvi melanoma treatment. Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer
• Positive Sentiment: Separate medical coverage reported a 50% response rate for lifileucel in patients with refractory undifferentiated pleomorphic sarcoma and liposarcoma. Positive activity in additional solid tumors strengthens the investment case for broader commercial and clinical applications. Lifileucel Shows 50% Response Rate in Refractory UPS and Liposarcoma
• Positive Sentiment: Zacks upgraded IOVA from “Hold” to “Strong Buy,” adding to the recent favorable momentum ratings and reinforcing bullish sentiment among some analysts. Zacks Research Stock Recommendations
• Neutral Sentiment: The company’s third-quarter results and corporate update are scheduled for November 5, creating a near-term event that could provide important information on Amtagvi sales, cash usage, and development plans. Iovance Third-Quarter 2026 Results Announcement
• Negative Sentiment: One analyst article cautioned that IOVA may already reflect much of the benefit from recent ESMO-related data, raising valuation and profit-taking risks after the stock’s substantial rally. Iovance Biotherapeutics Stock Could Look Fully Priced Despite ESMO Data

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc NASDAQ: IOVA is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.